Ken Cacciatore
Stock Analyst at TD Cowen
(0.31)
# 4,142
Out of 4,876 analysts
13
Total ratings
27.27%
Success rate
-28.39%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $13.74 | +263.90% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $6.46 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $15.10 | +32.45% | 4 | May 16, 2023 | |
| SCPH scPharmaceuticals | Initiates: Outperform | $25 | $3.87 | +545.99% | 1 | Dec 1, 2022 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $12.40 | +182.26% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $3.76 | +1,229.79% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $2.88 | +1,636.11% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $14.09 | +219.38% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $15.71 | +2,828.07% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $13.74
Upside: +263.90%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.46
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $15.10
Upside: +32.45%
scPharmaceuticals
Dec 1, 2022
Initiates: Outperform
Price Target: $25
Current: $3.87
Upside: +545.99%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $12.40
Upside: +182.26%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $3.76
Upside: +1,229.79%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $2.88
Upside: +1,636.11%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $14.09
Upside: +219.38%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $15.71
Upside: +2,828.07%